16 IPO Filings in 48 Hours—Tech and Nuclear Energy Drive Market Surge

Sixteen IPO filings landed in two days. That's not a slowdown—it's a market reawakening.

Between May 27 and 28, 2026, public markets attracted a diverse set of companies ready to go public: nuclear energy (Newcleo's SPAC merger), conversational AI (AISpeech), biotech, and traditional manufacturing. The filings span three continents and represent a clear shift in investor appetite toward essential infrastructure and AI-driven businesses.

The surge matters because IPO activity is a confidence indicator. When public markets are closed to new entrants, it signals institutional hesitation. When they reopen, it means capital allocators are ready to back companies at scale.

Nuclear and AI Dominate—A New Capital Story

Two companies stand out: Newcleo, going public via SPAC merger on Nasdaq, and AISpeech, pursuing a traditional IPO on China's Star Market (the tech-focused segment).

Newcleo's listing is striking. The nuclear technology company raised $1.05 billion in its SPAC combination. Five years ago, nuclear companies were seen as regulatory quagmires. Today, the combination of AI-driven energy demand and climate pressure has flipped perception. AI data centers consume enormous electricity. Nuclear plants are baseload power. The math is simple, and the capital market is pricing in demand.

AISpeech's filing tells a parallel story. Conversational AI is no longer speculative. Companies building speech recognition, voice synthesis, and language models are moving from private markets to public ones because revenue and path to profitability are now obvious. AISpeech competes with OpenAI, Google, and local players—and the market is willing to test their valuation.

Biotech Steady, Geographic Mix Broadens

Five of the 16 filings were biotech or pharmaceutical companies. This is not unusual—biotech tends to rely on public markets for capital-intensive clinical trials and FDA approval processes. What stands out is the geographic spread: four filings from China (including biotechs going through IPO approval on Shanghai and Beijing exchanges), three from Israel, five from the US, and four from other countries.

The Israel-US overlap is worth noting. Israeli tech and biotech firms often use SPAC mergers and US listings to access capital faster than traditional Nasdaq IPOs would allow. This option remains attractive.

China's filings are methodical. The biotech approvals came through the standard IPO committee process on Chinese exchanges. These filings are less about sentiment and more about regulatory flow—companies hitting milestones and proceeding with scheduled listings.

Why Now? Three Factors Converge

First, PE exits are finding a home. Private equity portfolios held for 5-7 years are reaching exit windows. Public markets offer IPO-hungry PE sponsors a direct path to return capital to LPs. The 16 filings likely include several PE-backed companies exiting into a receptive market.

Second, energy security and AI infrastructure are investment orthodoxy. Five years ago, data center infrastructure was niche. Today, it's core to every institutional mandate. Nuclear energy went from "too risky" to "essential." When consensus shifts, IPO underwriters get busy. Companies that raised private capital at 2-3 year intervals now have a clear path to public markets before additional capital rounds.

Third, regulation is predictable. US IPO disclosure requirements are well understood. China's approval process is methodical. Israeli tech can navigate US markets with proven path through SPAC sponsors. Uncertainty has not disappeared—but it's not at 2024 levels either. That clarity opens the IPO window.

What Happened to Older IPO Waves?

The May 23 IPO surge we covered two weeks ago included Cerebras ($5.5B valuation), a semiconductor AI company. That wave was 107 filings over a longer period and predominantly tech-heavy. This 16-filing cluster is faster but more diversified: energy, health, AI, traditional manufacturing sharing headlines.

Cerebras went public via traditional IPO at a $5.5B valuation after months of underwriter roadshows. Newcleo is following a SPAC path—faster, less roadshow overhead. Both reflect the same phenomenon: AI and energy infrastructure companies can now reliably attract institutional capital at IPO. The mechanism varies (traditional vs SPAC), but the confidence is identical.

The Valuation Question

We don't have detailed IPO pricing for most of these 16 filings—the filings are recent, pricing will follow. But historical context is worth noting: biotech IPOs averaged 40-60% first-day pops in 2025-2026 when demand was high and supply was constrained. Energy and nuclear filings are rarer, so underpricing risk is higher.

Newcleo's $1.05B raise is chunky for a single SPAC combination. That suggests either (a) investors are confident in nuclear's ROI, or (b) Newcleo needed a large capital raise for next-phase infrastructure buildout. Likely both.

Global Capital Sees Opportunity Where Policy Aligns

US filings cluster around AI and biotech where private capital markets have been fully saturated—mega-rounds at mega-valuations leave no room for traditional IPOs except at eye-watering prices. Going public becomes cheaper and faster than staying private.

China's filings flow through existing approval channels at a steady state. The biotech approvals signal that China's private capital markets (dominated by government-backed and state-owned pools) continue to funnel excess capital into IPOs rather than venture rounds.

Israel's SPAC path is pure optionality—these companies could go traditional IPO, but SPAC sponsors offer speed and sponsor expertise. The Israeli tech ecosystem is small and mature, so public market access is more valuable than maintaining scarcity via extended private fundraising.

What This Means for June and Beyond

IPO calendars are forward-looking. A 16-filing cluster on May 27-28 means underwriters have confidence in pipeline demand for at least the next quarter. That confidence typically translates to 20-40 additional filings in the following 4-6 weeks as companies lock in roadshow dates and pricing timing.

Watch for three signals over the next 30 days:

1. Underpricing success: If these 16 companies debut with muted first-day gains (0-20%), institutional demand is rational and measured. If we see 40-60% pops, demand is overheated and future waves will face pricing pressure.

2. Lock-up expirations: Most IPOs impose 180-day lock-ups on existing shareholders. Companies going public in June will hit lock-up expirations in November-December. If insiders sell aggressively, it signals equity fatigue. If lock-up periods extend voluntarily, it signals confidence.

3. Follow-on offerings: Companies that raise capital in IPOs often follow with secondary offerings 9-12 months later if growth accelerates. The 16 companies in this wave will be monitored for follow-on timelines starting in Q1 2027.

Public markets are open. The question is not whether companies will go public in June—they will. The question is at what valuations, and what that reveals about how much air is priced into late-stage private companies that are not yet public.